GenREY's regenerative roadmap: seven active R&D programs sequenced across a disciplined three-phase plan that turns scientific platforms into deployed therapies and sovereign biotech infrastructure.
Human biology can be rebuilt, not just patched, when regenerative tools, intelligence, and infrastructure are deployed in coordination.
Advanced iREY device paired with proprietary DAMI follicular delivery and exosome-based serums. Subscription-based treatment model engineered for clinical and premium home use. GenREY's near-term commercial flagship.
Cofactor-selective androgen receptor modulators, biomarker-guided targeting, and localized delivery, engineered as a pharma licensing asset with reduced systemic side-effects versus standard therapies.
A sovereign-grade health-data and clinical-intelligence platform organizing rare-disease populations. Rare-disease registries, natural-history data, trial-readiness capabilities, and genomics-AI precision insights deployable under national governance.
Implant-free, biologically integrated reconstruction and augmentation. Stem-cell-enriched adipose platforms, biosynthetic dermal matrices, scar-sparing access systems, and future oncology biologics.
Hepatic regeneration, micro-liver validation systems, and progressive organogenesis, a strategic pillar in organ-replacement science and long-horizon bioengineering.
Longevity medicine, mitochondrial health programs, and premium regenerative wellness. Concierge-grade offerings for human performance optimization.
Strategic licensing, white-label commercialization, and rapid deployment across human, veterinary, and longevity applications. Initially targeting orthopedics and sports medicine for day-one revenue.
Three capital-staged milestones, each calibrated to specific scientific, clinical, and infrastructure deliverables.
For sovereign funds, ministries, and strategic capital. Brief on the phase that fits your mandate.